Crispr Therapeutics AG (NASDAQ:CRSP) was the recipient of a significant drop in short interest during the month of November. As of November 29th, there was short interest totalling 3,620,000 shares, a drop of 34.9% from the November 14th total of 5,560,000 shares. Approximately 10.6% of the company’s shares are short sold. Based on an average trading volume of 914,900 shares, the days-to-cover ratio is currently 4.0 days.

Several equities research analysts have weighed in on CRSP shares. Oppenheimer increased their target price on shares of Crispr Therapeutics from $65.00 to $80.00 and gave the stock an “outperform” rating in a report on Monday, November 25th. William Blair upgraded shares of Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, November 19th. Canaccord Genuity increased their target price on shares of Crispr Therapeutics from $72.00 to $80.00 and gave the stock a “positive” rating in a report on Wednesday, November 20th. Goldman Sachs Group increased their target price on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the stock a “neutral” rating in a report on Tuesday, November 19th. Finally, ValuEngine upgraded shares of Crispr Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, November 1st. Two investment analysts have rated the stock with a sell rating, two have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. Crispr Therapeutics has a consensus rating of “Buy” and an average target price of $69.54.

CRSP traded up $0.38 during mid-day trading on Thursday, hitting $66.03. The stock had a trading volume of 1,136,382 shares, compared to its average volume of 712,154. Crispr Therapeutics has a 1-year low of $22.22 and a 1-year high of $74.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32. The stock’s fifty day simple moving average is $57.87 and its 200-day simple moving average is $48.15. The firm has a market capitalization of $3.72 billion, a price-to-earnings ratio of -19.19 and a beta of 3.31.

Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, October 28th. The company reported $2.40 EPS for the quarter, topping analysts’ consensus estimates of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The business had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. As a group, research analysts expect that Crispr Therapeutics will post 0.65 earnings per share for the current fiscal year.

In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total value of $412,500.00. Following the transaction, the director now directly owns 7,500 shares of the company’s stock, valued at $412,500. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the transaction, the president now directly owns 33,618 shares in the company, valued at $2,353,260. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 56,118 shares of company stock worth $3,620,760. Insiders own 21.40% of the company’s stock.

Several large investors have recently modified their holdings of the stock. Benjamin Edwards Inc. raised its holdings in shares of Crispr Therapeutics by 96.4% during the second quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock worth $26,000 after acquiring an additional 268 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Crispr Therapeutics by 13.6% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,870 shares of the company’s stock worth $118,000 after acquiring an additional 343 shares during the period. Traynor Capital Management Inc. raised its holdings in shares of Crispr Therapeutics by 5.8% during the third quarter. Traynor Capital Management Inc. now owns 6,845 shares of the company’s stock worth $280,000 after acquiring an additional 375 shares during the period. Commonwealth Equity Services LLC raised its holdings in shares of Crispr Therapeutics by 2.2% during the third quarter. Commonwealth Equity Services LLC now owns 18,201 shares of the company’s stock worth $746,000 after acquiring an additional 386 shares during the period. Finally, D. E. Shaw & Co. Inc. raised its holdings in shares of Crispr Therapeutics by 7.1% during the second quarter. D. E. Shaw & Co. Inc. now owns 7,019 shares of the company’s stock worth $331,000 after acquiring an additional 467 shares during the period. Institutional investors and hedge funds own 49.82% of the company’s stock.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Article: What is the market perform rating?




Source link